Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer

K. Matsui, N. Masuda, M. Fukuoka, T. Yana, T. Hirashima, T. Komiya, M. Kobayashi, M. Kawahara, S. Atagi, M. Ogawara, S. Negoro, S. Kudoh, K. Furuse

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.

Original languageEnglish (US)
Pages (from-to)1961-1965
Number of pages5
JournalBritish Journal of Cancer
Volume77
Issue number11
DOIs
StatePublished - Jun 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer'. Together they form a unique fingerprint.

Cite this